Mymd Pharmaceuticals (NASDAQ:QCLS) Posts Quarterly Earnings Results

Mymd Pharmaceuticals (NASDAQ:QCLS) issued its earnings results on Wednesday. The company reported ($0.79) EPS for the quarter, Zacks reports.

Mymd Pharmaceuticals Price Performance

NASDAQ QCLS remained flat at $2.89 during trading on Wednesday. The company’s stock had a trading volume of 48,502 shares, compared to its average volume of 674,812. The stock has a market cap of $12.04 million, a PE ratio of -0.14 and a beta of 2.16. Mymd Pharmaceuticals has a 12-month low of $2.50 and a 12-month high of $10.79. The business has a fifty day simple moving average of $3.48.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a research note on Friday. Wall Street Zen downgraded Mymd Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Mymd Pharmaceuticals has an average rating of “Sell”.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.